Funding for Research in HIV Prevention Continues to Drop
Financial support for the research and development (R&D) of HIV prevention declined in 2020, marking a drop for the second year in a row and continuing an eight-year trend of either decreased or flat funding, according to the latest annual report on the topic from AVAC, a global organization focused on HIV prevention.
December 28, 2021 — POZ
FDA Approves First Long-Acting Injectable to Prevent HIV Infection
The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months, then every 2 months afterwards. It is the first long-acting injectable for pre-exposure prophylaxis (PrEP). The drug is approved for adults and adolescents weighing at least 77 lb.
December 22, 2021 — MedPage Today
Although PrEP is Largely Underutilized, Developing Strategies Aim to Increase Initiation
There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from the AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.
December 22, 2021 — Contagion Live
Strategies Are Developing to Boost HIV PrEP Initiation
There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.
December 15, 2021 — HCP Live
How HIV Research Paved the Way for the COVID mRNA Vaccines
Every Dec. 1, the world commemorates those who have died from an AIDS-related illness. Known as World AIDS Day, it serves as a reminder that there has been an ongoing pandemic for the past 40 years, pre-dating COVID. The COVID vaccines were sequenced, developed and approved in the US in record time, but that would not have been possible without decades of work by HIV researchers.
December 1, 2021 — CNBC
The Current
The COVID-19 pandemic has complicated — and in some cases halted — the fight against HIV/AIDS. We talk about that impact with Hombisa Ntsikanye, an implementer and developer of the HIV and AIDS program at Blue Roof Life Space in Durban, South Africa; and Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition.
December 1, 2021 — CBC
COVID Has Hurt the Fight Against AIDS, Experts Say — But It Could Also Lead to an HIV Vaccine
Dr. Anthony Fauci, the top US infectious disease expert, said Tuesday the COVID-19 pandemic has diverted scientific and financial resources from the fight against AIDS, seriously impeding global efforts to achieve the UN goal of ending AIDS by 2030.
December 1, 2021 — NBC News
An HIV-Prevention Drug Is Widely Available. Yet At-Risk Women Are Getting Left Behind
In the US, women account for a fifth of new infections. But a persistent lack of education means few even know about the highly effective medication known as PrEP.
December 1, 2021 — National Geographic
Shifts in UNAIDS Ethics Guidance and Implications for Ethics Review of Preventive HIV Vaccine Trials
There have been several shifts in the UNAIDS ethics guidance with implications for HIV vaccine researchers submitting applications for initial ethics review or re-certification, and for RECs conducting such reviews. This review may assist RECs in a more efficient and consistent application of ethics recommendations. However, additional tools and training may further help stakeholders comply with new UNAIDS ethics recommendations during protocol development and ethics review.
November 21, 2021 — JIAS
HIV Prevention Today: Do We Still Need a Vaccine? A Community Perspective
Despite tremendous advances made in the global HIV response, overall progress in HIV prevention efforts remains too slow to reach the 2030 targets. In 2019 alone, 1.7 million people acquired HIV, three times more than the UNAIDS 2020 target. About 62 percent of the new infections were among key populations, these are men who have sex with men, sex workers, transgender people and people who inject drugs, and their sexual partners, and one in four new infections in sub-Saharan Africa are among adolescent girls and young women.
November 21, 2021 — JIAS
To Save Lives, Confirm Dr. John Nkengasong to Head PEPFAR by World AIDS Day
We were among the many advocates and global health leaders who called on the Biden Administration to move quickly in naming a permanent head for the US President’s Emergency Plan for AIDS Relief. Now that President Biden has selected Dr. John Nkengasong as his nominee, Congress must act swiftly to confirm his nomination and give US global efforts to address HIV – a preventable and treatable disease that still claims nearly 700,000 lives a year around the world, four decades after the first case was discovered – the permanent leadership it needs and deserves.
October 29, 2021 — Science Speaks
HIV Prevention in a Time of COVID-19: A Report From the HIVR4P // Virtual Conference 2021
HIVR4P // Virtual was held over the course of two weeks on 27-28 January and 3-4 February 2021 as the COVID-19 pandemic continued to inflict unprecedented harm globally. The HIVR4P community came together with 1,802 researchers, care providers, policy-makers, implementors and advocates from 92 countries whose expertise spanned the breadth of the HIV prevention pipeline from pre-clinical to implementation. The program included 113 oral and 266 poster presentations. This article presents a brief summary of the conference highlights.
October 29, 2021 — AIDS Research and Human Retroviruses
COVID-19 Has Killed More People in the US Than HIV/AIDS Did in 40 years
COVID-19 has now killed about 730,000 people in the US, making it the deadliest pandemic in the nation’s history, with more lives claimed than by HIV/AIDS. The tally comes as the US marks four decades since HIV — the virus that can cause AIDS — was first detected in the country, and some are now looking at the two vastly different diseases and seeing parallels. The US government’s initial approach to both HIV/AIDS and COVID was denial and indifference.
October 21, 2021 — The National News
Initiatives To Accelerate the Long and Difficult Search for an HIV Vaccine
It is paradoxical that the speed in obtaining vaccines against COVID-19 is due, in large part, to the enormous advantage provided by research on HIV and its key technologies and that, however, we still continue without an immunization against the virus AIDS. To move forward, we need increased funding and consistent commitment from the industry.
October 14, 2021 — Agencia SINC
John Nkengasong, Ph.D., Is Biden’s Pick to Fill the Long-Empty Role of US Global AIDS Czar
In June, we reported that PEPFAR, the $7 billion US global-AIDS relief program started by President George W. Bush in 2003, had been leaderless for more than a year. This left global AIDS advocates worried that the program was losing momentum and focus, especially amid the new global pandemic of COVID-19.
October 12, 2021 — TheBody
First COVID, Now HIV. Moderna and San Diego Researchers Race To Make a Vaccine
Researchers plan to use a series of shots to teach people’s immune systems to produce powerful antibody responses against the virus. But while the strategy is raising hopes and is built on years of research, there’s no guarantee it succeeds.
October 7, 2021 — San Diego Union-Tribune
Nkengasong Eyes Big Job at PEPFAR, but Africa CDC May Miss Him
Just how will the Africa Centres for Disease Control (Africa CDC) run after its famed leader John Nkengasong leaves? The answer may not be apparent, but the Cameroonian-American virologist, who has recently become the face of Africa’s campaign for vaccine equity, could be departing the organisation soon.
September 28, 2021 — The East African
Public Health Leader Will Be First African to Helm PEPFAR
For the first time in its 18-year history, the President’s Emergency Plan For AIDS Relief (PEPFAR) will be headed by an African public health leader, according to a report in theNew York Times. President Joe Biden plans to appoint John Nkengasong, MD, as head of the federal agency that serves people living with HIV worldwide.
September 27, 2021 — POZ
Nkengasong’s Bittersweet Departure From Africa CDC
United States President Joe Biden is reportedly nominating Dr. John Nkengasong, director of the Africa Centres for Disease Control and Prevention, to head the US President’s Emergency Plan for AIDS Relief, a $7 billion operation. The US government initiative has been without a leader since February. The Cameroonian virologist would be the first person from the African continent to head the program.
September 22, 2021 — Devex
The Race To Vaccinate: Why Africa Is Struggling To Get COVID Jabs
Vaccines were promoted as a silver bullet to end the pandemic, the path to finally beating COVID-19. But in Africa, they remain scarce, with access hampered by hoarding, export bans and empty promises. Nearly six billion vaccine doses have been administered globally, but only two percent of those have been in Africa.
September 21, 2021 — France 24
John Nkengasong, of the Africa CDC, Will Lead PEPFAR
The Biden administration plans to nominate John Nkengasong, a virologist and director of the Africa Centers for Disease Control and Prevention, to lead the President’s Emergency Plan for AIDS Relief, according to several sources familiar with the matter.
September 21, 2021 — New York Times
Integration of HIV and Sexual and Reproductive Health in the Era of Anti-Retroviral-Based Prevention: Findings From Assessments in Kenya, Malawi and Zimbabwe
As new HIV prevention products are introduced, demand for integrated HIV/SRH services is likely to grow. Investing in HIV/SRH integration can help to ensure sustainable, government-led responses to the HIV epidemic, streamline service delivery and improve the health outcomes and lives of AGYW.
September 15, 2021 — Gates Open Research
Imbokodo Trial Results Highlight Challenge of Developing an HIV Vaccine and Urgent Need for Access to Proven Prevention Tools
At the end of August, disappointing results were released from Imbokodo, a phase IIb clinical trial evaluating the efficacy of an HIV vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Among cisgender women recruited in five African countries, the vaccine regimen didn’t offer significant protection against acquisition of HIV infection. The outcome underscores the difficulty of inducing protective immunity against HIV compared to other pathogens, and highlights the importance of making effective biomedical prevention options—oral or injectable pre-exposure prophylaxis (PrEP) and the dapavirine ring—accessible to those in need, including women in the communities where Imbokodo took place.
September 13, 2021 — Treatment Action Group
The Latest Big HIV Vaccine Disappointment Means We Must Double Down on Other Prevention Methods
The news on Aug. 31 was devastating: After a decade of research and development, Johnson & Johnson announced that its experimental HIV vaccine showed no clear ability to prevent infection. Such was the unhappy end of the so-called Imbokodo study—the word means a “grinding rock” in Zulu and is attached to a famous saying about the strength of women. … The results showed 63 new HIV infections among the women who got the placebo and 51 among women who got the vaccine—hardly a big enough difference to suggest that the vaccine was a grand slam.
September 9, 2021 — The Body
The Pandemic Has Set Back the Fight Against HIV, TB and Malaria
The COVID-19 pandemic has severely set back the fight against other global scourges like HIV, tuberculosis and malaria, according to a sobering new report released on Tuesday. Before the pandemic, the world had been making strides against these illnesses. Overall, deaths from those diseases have dropped by about half since 2004. “The advent of a fourth pandemic, in COVID, puts these hard-fought gains in great jeopardy,” said Mitchell Warren, executive director of AVAC….
September 7, 2021 — New York Times
Africa HIV Vaccine Trial Fails
An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organisers say. According to a statement released this week (31 August) by Johnson & Johnson (J&J), the US drugmaker that produced the HIV vaccine candidate, the mid-stage Imbokodo study began in 2017, reached full enrollment in 2019 and completed vaccinations on 30 June 2020.
September 3, 2021 — SciDevNet
NIH on HIV Vaccine Failure: ‘Get Your HIV-Negative, At-Risk Patients on PrEP Tomorrow’
The results [of HVTN 705, known as the Imbokodo study] are frustrating, said Carl Dieffenbach, PhD, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID). To clinicians, Dieffenbach said the message of this HIV vaccine trial is flush with urgency: “Get your HIV-negative, at-risk people on PrEPtomorrow.”
September 2, 2021 — Medscape
Will the Moderna HIV Vaccine Trials Succeed?
For decades, a successful HIV vaccine has been an elusive concept for scientists and activists. During the last two years, research regarding HIV/AIDS hasn’t garnered as much media attention largely due to the COVID-19 pandemic. But just because it hasn’t grabbed as many headlines, doesn’t mean it isn’t still a prevalent issue today. According to the UNAIDS, in 2020, 1.5 million people around the world were newly infected and 680,000 died due to AIDS-related illnesses.
September 1, 2021 — PAPER
An Experimental HIV Vaccine Fails in Africa
An advanced HIV vaccine trial in Africa has been shut down after data showed the shots offered only limited protection against the virus, researchers announced on Tuesday. The vaccine, made by Johnson & Johnson, is one in a long line found to offer little defense against HIV, one of medicine’s most intractable adversaries.
August 31, 2021 — New York Times
J&J Halts Africa HIV Vaccine Trial as Prevention Falls Short
Johnson & Johnson stopped a mid-stage test of its HIV vaccine in southern Africa after the shot showed insufficient ability to protect people from contracting the virus. The trial, called Imbokodo, showed the vaccine was just 25 percent effective in preventing HIV infection over a period of two years, short of a goal of 50% efficacy, according to a statement. A similar vaccine developed by the drugmaker will continue being tested in Europe and the Americas in a final-stage study called Mosaico, Paul Stoffels, J&J’s chief scientific officer, said.
August 31, 2021 — Bloomberg
The Sputnik Vaccine Case Study (Part Two): How Fast Is Too Fast?
In June,Bhekisisastarted doing research for an article that would explain how well Russia’s Sputnik V vaccine works and to gauge whether it would be suitable for use in South Africa’s COVID-19 vaccine roll-out. Soon enough, it was realised Sputnik V had flouted the rules of every part of the system that produces scientific research.
August 24, 2021 — Daily Maverick
How Fast Is Too Fast? In the Driver’s Seat With the Pandemic’s Peer Reviewers
During the pandemic, researchers and academic journals have gone into hyperdrive in order to produce research at an accelerated pace. This means some sacrifices have been made when it comes to vetting and checking publications through peer review. The peer-review system was already flawed even in pre-pandemic times but the current environment has exposed ways in which bad science can slip through.
August 20, 2021 — Health 24
How Can HIV Research Better Align With the Realities of Transgender and Gender Diverse People?
Transgender and gender diverse activists and researchers, in partnership with the advocacy organisation AVAC, introduced a powerful manifesto to align HIV prevention research with their current realities and needs, entitledNo Data No Moreat the 11th International AIDS Society Conference on HIV Science (IAS 2021) this week.
July 22, 2021 — aidsmap
An HIV Prevention Manifesto by Transgender and Gender-Diverse People
Transgender women experience higher rates of HIV than most other populations. Globally, it’s estimated that 19 percent of trans women are living with HIV, 49 times the general population; conversely, not much is known about HIV among transgender men and nonbinary people. Given these facts, why aren’t more transgender and gender-diverse (TGD) people included in HIV-related research and prevention efforts?
July 19, 2021 — POZ
Tired of Being Excluded from HIV Research, Transgender People Issue Manifesto
Almost one in five trans women globally are living with HIV – 49 times greater than the general population – while HIV in trans men is woefully understudied. Yet trans and gender-diverse (TGD) people are “frequently and often systematically left out of HIV prevention research and responses”, according toNo Data No More, a global HIV prevention manifesto launched on Monday with the support of the non-profit HIV prevention organisation, AVAC.
July 19, 2021 — Health Policy Watch
UN Shift on HIV Prevention Raises Hope We Can End AIDS by 2030 – Now We Need To Turn Words Into Action
The latest UN Declaration on AIDS does not speak more forcefully on the need to protect the human rights of key populations at risk for HIV, but there are significant shifts, including an unprecedented commitment to HIV combination prevention.
July 16, 2021 — Daily Maverick
Opinion: US Leadership Matters in Fighting AIDS
US President Joe Biden has repeatedly praised the United States’ leadership in the global effort to end HIV/AIDS. Early this month, in marking the 40th anniversary of the start of the AIDS pandemic, the White House noted the “heartbreaking human toll” of nearly 35 million global AIDS deaths, the ongoing, high rate of new HIV infections worldwide, and the enormous progress being made against the epidemic by the US President’s Emergency Plan for AIDS Relief, or PEPFAR.
June 28, 2021 — Devex
Integrating Oral PrEP Into Family Planning Services for Women in Sub-saharan Africa: Findings From a Multi-Country Landscape Analysis
Our framework offers policymakers, program implementers, and health care providers a road map for strategically assessing and monitoring progress toward PrEP-FP integration in their contexts.
June 18, 2021 — Frontiers in Reproductive Health
UN 5th High Level Meeting on HIV/AIDS: Civil Society Says “Yes — AND” to the 2021 Political Declaration
On Tuesday (June 8), the UN General Assembly voted overwhelmingly to approve the 2021 Political Declaration on HIV and AIDS introduced as part of the now fifth High Level Meeting on HIV/AIDS. Previous Declarations were accepted by unanimous consent, following months of negotiations. This year’s Political Declaration includes much to applaud, including new ambitious targets for prevention, investment goals to ensure everyone who needs treatment has access to it, and a financial and moral commitment to end gender inequality, stigma and discrimination.
June 14, 2021 — Science Speaks
Tackling Pandemics Means Relearning the Lessons of Fighting HIV
This week, the World Health Assembly (WHA), the governing body of the World Health Organization, is grappling with how best to prepare for and ideally prevent future pandemics. The WHA is taking as its starting point recommendations from the Independent Panel for Pandemic Preparedness and Response, which issued its findings earlier this month. The report is toothier and more specific than prior comparable commissions but has also generated debate over if and how to create a global governing body for pandemic action.
May 30, 2021 — Foreign Policy
HIV Vaccine Awareness Day 2021
Tuesday, May 18, marks HIV Vaccine Awareness Day (#HVAD) 2021. It’s designated as a time to thank the researchers, community leaders, health professionals and volunteers working to develop a vaccine to prevent HIV/AIDS. It’s also a day to educate the public about advancements in vaccine research and raise awareness about the need for an HIV vaccine.
May 18, 2021 — POZ
Finding an HIV Vaccine: Five Lessons From the Search for a COVID Jab
The way in which the world has responded to COVID, has fundamentally changed ideas of what’s possible in vaccine development—but, regrettably, access to that scientific knowledge remains the property of a few drug companies and research institutions in wealthy countries.
May 18, 2021 — Bhekisisa
We Need an HIV Vaccine. Here’s What You Can Do to Help
First celebrated in 1998, a little more than a decade after the launch of the very first HIV vaccine study, HIV Vaccine Awareness Day (HVAD), observed each May 18, is an opportunity to spotlight the ongoing global efforts to develop a safe and effective vaccine against HIV.
May 18, 2021 — HIV Plus Mag
There’s No Hidden US Vaccine Stockpile Ready to Send Abroad
America led the world in buying up the messenger RNA vaccines that have proven most effective against COVID-19. It’s now starting to lead the world in not using them.
May 15, 2021 — Bloomberg
RV144: The Largest HIV Vaccine Trial in History
In a little under a year, scientists developed several vaccines against COVID-19. But as we line up for our shots, we are still living in the shadow of another pandemic. The search for a vaccine against HIV, the virus that causes AIDS, has been ongoing for nearly four decades. To this day, only one large-scale trial has demonstrated even marginal efficacy at preventing infection from the virus: the RV144 trial in Thailand—the largest HIV vaccine trial in history.
May 8, 2021 — JSTOR Daily
NGO Cries Out Over 100,000 Daily HIV Infection Rate
A Non-Governmental Organisation (NGO), Heartland Alliance, has expressed worry about the alarming HIV infections in Nigeria, currently at 100,000 per day. Mr. Michael Akanji, a resource person, speaking at a media roundtable organised by the NGO and the AVAC 2020/2021 Fellowship Programme at the weekend in Uyo, Akwa Ibom State, decried the continued high rating of Akwa Ibom in HIV Prevalence Rating in the country.
May 3, 2021 — The Nation
Scientists Say the Technology Behind COVID-19 mRNA Vaccines Could Be Adapted to an HIV Vaccine
The COVID-19 pandemic has lasted only slightly more than a year; the AIDS epidemic, by contrast, now spans decades. Just as AIDS has taken more than 670,000 lives in this country, scientists have long dreamed of a day when they could inoculate the population against HIV, the virus which causes the deadly disease.
April 9, 2021 — Salon
Can Unprecedented Success in COVID Vaccine Development Boost Prospects for an HIV Vaccine?
In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN 702, or Uhambo, was halted for lack of efficacy. Researchers and advocates had high hopes for Uhambo, building as it did on the RV144 trial, which provided the first evidence that an HIV vaccine could create a partially protective immune response. But Uhambo, like several studies before it, ended in disappointment.
April 7, 2021 — Science Speaks
Major Conference on HIV and COVID-19 Under Fire for Putting Science Behind Paywall
In the shut-down world of COVID-19, medical science conferences take place virtually—and protests do, too. Such was the case this week during the Conference on Retroviruses and Opportunistic Infections (CROI 2021), which from March 6 to March 10 featured breaking, clinically important research on HIV and the novel coronavirus.
March 11, 2021 — The BodyPro
Will We Ever Have a HIV Vaccine?
Crises have a habit of accelerating history, including the pace of technological advancement. The COVID-19 pandemic is no exception. Vaccines were developed, safely but with unprecedented efficiency, less than a year after the WHO declared a global pandemic.
February 23, 2021 — Vaccines Today
Can New Ethical Guidelines Reshape HIV Prevention Trials?
In a bid to include ethical considerations in the HIV prevention trial process UNAIDS and the World Health Organisation recently launched a new guidance document for ethical consideration for HIV prevention trials. The guidance among other things, calls for the inclusion of communities that live in settings where trials are taking place as equal partners.
February 12, 2021 — Devex
Why Broadly Neutralising Antibodies Might Be the Next Big Thing in HIV
Results of a “proof of concept” study presented at the virtual 4th HIV Research for Prevention Conference last week showed that one particular broadly neutralising monoclonal antibody (bNAb) – called VRC01 – prevented HIV infection in over 70 percent of people exposed to strains of HIV that is sensitive to this particular bNAb.
February 8, 2021 — Spotlight
African Studies Explore Reasons To Start, Stick With or Stop PrEP
This year’s HIV Research for Prevention (HIVR4P) virtual conference featured a large number of sessions examining PrEP usage and discontinuation rates among a variety of users, especially in Africa. Many of the presentations looked at factors that worked as incentives to keep taking PrEP. There is interest in this because, despite higher initiation rates in a larger number of countries than ever before, the retention rates (also called persistence rates) of people in PrEP programmes in the region remain very low.
February 8, 2021 — aidsmap
HIV Science Has Advanced but Policies-Programmes Have Been Slow to #endAIDS
HIV science has advanced but policies and programmes have been slow to respond towards ending AIDS, said Mitchell Warren, co-chair of the global conference on HIV Research for Prevention (HIVR4P) and Executive Director of AVAC.
February 7, 2021 — CNS
Funding for COVID-19 Overshadows HIV/TB Research Expense
Global funding for COVID-19 vaccine development has exceeded 10 times in less than a year the amount allocated for HIV and TB research and development in 11 years.
February 6, 2021 — The International News
Africa’s Success in Rapidly Rolling Out HIV Prevention Measure, PrEP
When Wasiu spoke toDevexin 2018 about his HIV-positive status and the statuses of his three wives, the two living with him in Nigeria had tested positive for HIV while the one in the United States was HIV-negative due to distance and her ability to access pre-exposure prophylaxis, or PrEP.
February 5, 2021 — Devex
African Nations Lead the World in Offering PrEP HIV Prevention Drug
Nearly 1 million people are now taking pre-exposure prophylaxis (PrEP), medicine that can slash the risk of HIV infections. While early use of the drug was mostly limited to Western nations, the number of users in sub-Saharan Africa (SSA) has now drastically increased, accounting for more than half of the world’s PrEP users.
February 2, 2021 — New Scientist
Nearly a Million Have Started Taking PrEP Worldwide – Only a Third of UNAIDS’ 2020 Target
Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been dependent on far-reaching factors that go beyond how well PrEP is able to prevent HIV acquisition at a cellular level: political leadership, quality health services and funding.
February 1, 2021 — aidsmap
A Pill, a Ring or a Jab: The future of HIV prevention is choice
South Africa is ahead of local targets in rolling out the HIV prevention pill. Meanwhile, options for HIV prevention are expanding — though the devil is in the detail of getting medicines to people in a way that works for them.
January 27, 2021 — Daily Maverick
AMPing up HIV Prevention: An inside look at how the immune system fights off the virus
New pivotal research, the first of its kind to announce results, builds on ideas from vaccination and tests a new idea: whether special antibodies — the type that can help someone fight off multiple forms of the virus — can be used to prevent HIV infection.
January 27, 2021 — Bhekisisa
Important Advances in HIV Prevention Unveiled: New PrEP Formulas & Broadly Neutralizing Antibodies
While global attention has fixated on the coronavirus, the forty-year long fight against HIV, which has claimed 33 million lives, is seeing new breakthroughs in preventive tools. New discoveries of “broadly neutralizing antibodies” as well as novel regimens of pre-exposure prophylaxis (PrEP), could strengthen the world’s toolbox to prevent the disease, announced the International AIDS Society (IAS) at the opening of the 4th HIV Research for Prevention Conference.
January 27, 2021 — Health Policy Watch
HIV PrEP Uptake Increases Sixfold in 4 Years, Still Falls Sort of Global Goals
HIV PrEP uptake has increased sixfold globally in the last 4 years but remains short of the UNAIDS target of 3 million users, according to data reported during the HIV Research for Prevention virtual conference.
January 26, 2021 — Healio
Anthony Fauci: “I Don’t Do This Because I’m a Hero. I Do It Because It’s Necessary.”
“The enormity of the problem is how I keep going,” Dr Anthony Fauci told a meeting of global health journalists yesterday. “I haven’t had a single day off since 20th January last year, but the necessity of dealing with the COVID epidemic is an anaesthetic against fatigue.”
January 14, 2021 — aidsmap
→ Continue through the archives. Find articles from 2020 and older.